Cargando…

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death

INTRODUCTION: The Campath, Calcineurin inhibitor (CNI) reduction, and Chronic allograft nephropathy (3C), a study comparing alemtuzumab versus basiliximab induction immunosuppression in kidney transplants, has found lower acute rejection rate with alemtuzumab but same graft survival. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asderakis, Argiris, Sabah, Tarique K., Watkins, William J., Khalid, Usman, Szabo, Laszlo, Stephens, Michael R., Griffin, Sian, Chavez, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039467/ https://www.ncbi.nlm.nih.gov/pubmed/35497810 http://dx.doi.org/10.1016/j.ekir.2022.01.1042

Ejemplares similares

Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk – a retrospective analysis of UNOS database
por: Ali, Hatem, et al.
Publicado: (2023)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
por: Furukawa, Masashi, et al.
Publicado: (2022)

Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction
por: Weissenbacher, Annemarie, et al.
Publicado: (2015)

SARS-CoV-2 in Kidney Transplant and Waitlisted Patients During the First Peak: The Welsh Experience
por: Khalid, Usman, et al.
Publicado: (2021)

Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013)

An avoidable cause of thymoglobulin anaphylaxis
por: Brabant, S., et al.
Publicado: (2017)

Severe Intraoperative Anaphylaxis Related to Thymoglobulin during Living Donor Kidney Transplantation
por: Saeed, Muhammad I., et al.
Publicado: (2020)

Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations
por: Kunacheewa, Chutima, et al.
Publicado: (2020)

Thymoglobulin – new approaches to optimal outcomes
por: Delia Moiceanu, Andreea, et al.
Publicado: (2009)

SARS-CoV-2 Infection Can Lead to an Increase in Tacrolimus Levels in Renal Transplant Patients: A Cohort Study
por: Chalklin, Christopher G., et al.
Publicado: (2022)

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
por: Green, Kile, et al.
Publicado: (2017)

Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial
por: Ajlan, Aziza, et al.
Publicado: (2021)

Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
por: Lee, Jun Young, et al.
Publicado: (2022)

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
por: Hong, Su Yeon, et al.
Publicado: (2023)

The role of basiliximab in the evolving renal transplantation immunosuppression protocol
por: Salis, Paola, et al.
Publicado: (2008)

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment
por: Deng, Dao-Xing, et al.
Publicado: (2022)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study
por: Qiu, Jiang, et al.
Publicado: (2019)

P1292: BASILIXIMAB MAY BE THE POTENTIAL SOLUTION FOR SEVERE LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE PILOT STUDY
por: Deng, Dao-Xing, et al.
Publicado: (2023)

Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression
por: Zuckermann, Andreas, et al.
Publicado: (2015)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020)

Grafalon® vs. Thymoglobulin® as an Induction Agent in Renal Transplantation – A Retrospective Study
por: Jha, Pranaw Kumar, et al.
Publicado: (2021)

Comparison of alemtuzumab, anti-thymocyte globulin, and post-transplant cyclophosphamide for graft-versus-host disease and graft-versus-leukemia in murine models
por: Mashima, Kiyomi, et al.
Publicado: (2021)

Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
por: Wang, Ricardo, et al.
Publicado: (2015)

Basiliximab/steroids/tacrolimus: Pneumonia with Scedosporium apiospermum and Lomentospora prolificans: case report
Publicado: (2021)

Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates
por: Kim, Ha Eun, et al.
Publicado: (2021)

A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
por: Jardine, Laura, et al.
Publicado: (2015)

The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease
por: Ali, Robert, et al.
Publicado: (2017)

A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition
por: Barten, Markus J., et al.
Publicado: (2016)

Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
por: Toor, A, et al.
Publicado: (2008)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center
por: Khalafi-Nezhad, A., et al.
Publicado: (2015)

Is Thymoglobulin or Rituximab the Cause of This Serum Sickness? A Case Report of Serum Sickness Dilemma and Literature Review
por: Sandhu, Amarpreet, et al.
Publicado: (2012)

Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?
por: Hardinger, Karen L., et al.
Publicado: (2010)

New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin(®)) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity
por: Mohty, Mohamad, et al.
Publicado: (2014)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study
por: Widman, Guido, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iudfd5hjl697alsnetqrisvoab